Pediatric Fulminant Hepatic Failure Medication
- Author: Hisham Nazer, MB, BCh, FRCP, DCh, DTM&H; Chief Editor: Carmen Cuffari, MD more...
Medication Summary
No definite treatment is available for fulminant hepatic failure (FHF). Medical treatment is usually directed at causative agents or at minimizing morbidity or mortality caused by serious complications.
Vitamins
Class Summary
Vitamins are organic substances required by the body in small amounts for various metabolic processes. They may be synthesized in small or insufficient amounts in the body or not synthesized at all, thus requiring supplementation.
Phytonadione (AquaMEPHYTON, Mephyton)
Vitamin K is a fat-soluble vitamin absorbed by the gut and stored in the liver. It is necessary for function of clotting factors in the coagulation cascade and, thus, is used in coagulopathy resulting from liver failure.
Hyperosmotic Agents
Class Summary
Hyperosmotic agents such as lactulose work by increasing the amount of stool water content and softening the stool, allowing for an increased number of bowel movements per day. They also cause decreases in the blood ammonia concentration.
Lactulose (Cephulac)
Lactulose inhibits diffusion of NH3 into blood by producing an acidic pH that causes the conversion of NH3 to NH4, a nondiffusable form of ammonia. It is also used to evacuate the bowel and reduce intestinal stasis.
Aminoglycosides
Class Summary
Aminoglycosides such as neomycin are used as adjunctive therapy to reduce the number of ammonia-forming intestinal bacteria.
Neomycin (Mycifradin)
Neomycin interferes with bacterial protein synthesis by binding to 30S ribosomal subunits, thus reducing the number of ammonia-producing bacteria in the intestine. The subsequent reduction in blood ammonia has resulted in neurologic improvement. Agents such as neomycin are used to prevent and treat portal systemic encephalopathy.
Osmotic diuretics
Class Summary
Osmotic diuretics may reduce subarachnoid space pressure by creating an osmotic gradient between cerebrospinal fluid in the arachnoid space and plasma. They are not for long-term use.
Mannitol (Osmitrol, Resectisol)
Mannitol is used to decrease intracranial pressure. Mannitol is used in patients with documented intracranial pressure greater than 30 mm Hg and can be considered in patients with progressive edema.
Antiviral agents
Class Summary
Antiviral agents inhibit activity of herpesvirus types 1 and 2. They have affinity for viral thymidine kinase and, once phosphorylated, cause DNA chain termination when acted on by DNA polymerase.
Acyclovir (Zovirax)
Acyclovir is a synthetic purine nucleoside analogue. Hepatitis is treated with acyclovir for herpesvirus hepatitis.
Antidotes
Class Summary
These agents are used in the management of poisoning and overdose, for prevention of toxic effects, or for metabolic disorders when toxic substances accrue.
N-acetylcysteine (Mucomyst)
N-acetylcysteine is indicated in acetaminophen toxicity. It may provide a substrate for conjugation with a toxic metabolite of acetaminophen. All doses should be administered, even if the acetaminophen level has dropped below the toxic range.
Immunosuppressive agents
Class Summary
These agents are used in autoimmune hepatitis for immunosuppression effect.
Prednisone (Deltasone, Orasone)
Prednisone is an immunosuppressant for treatment of autoimmune disorders; it may decrease inflammation by reversing increased capillary permeability and suppressing polymorphonuclear leukocyte activity. It stabilizes lysosomal membranes and suppresses lymphocytes and antibody production.
Azathioprine (Imuran)
Azathioprine antagonizes purine metabolism and inhibits synthesis of DNA, RNA, and proteins. It may decrease proliferation of immune cells, which results in lower autoimmune activity.
Histamine H2 antagonists
Class Summary
These agents inhibit histamine stimulation of the H2 receptor in gastric parietal cells, which, in turn, reduces gastric acid secretion, gastric volume, and hydrogen concentrations. These agents are used to prevent stress ulcer development and potential gastrointestinal (GI) bleeding.
Ranitidine (Zantac)
A parenteral H2-receptor blocker is administered prophylactically to prevent potential GI bleeding. Ranitidine is indicated in peptic ulcer disease and upper GI bleeding for both treatment and prophylaxis.
Gotthardt D, Riediger C, Weiss KH, Encke J, Schemmer P, Schmidt J, et al. Fulminant hepatic failure: etiology and indications for liver transplantation. Nephrol Dial Transplant. Sep 2007;22 Suppl 8:viii5-viii8. [Medline].
Cochran JB, Losek JD. Acute liver failure in children. Pediatr Emerg Care. Feb 2007;23(2):129-35. [Medline].
Lee WS, McKiernan P, Kelly DA. Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United kingdom. J Pediatr Gastroenterol Nutr. May 2005;40(5):575-81. [Medline].
Baker A, Alonso ME, Aw MM, et al. Hepatic failure and liver transplant: Working Group report of the second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. Jun 2004;39 Suppl 2:S632-9. [Medline].
Dhawan A, Cheeseman P, Mieli-Vergani G. Approaches to acute liver failure in children. Pediatr Transplant. Dec 2004;8(6):584-8. [Medline].
Latif N, Mehmood K. Risk factors for fulminant hepatic failure and their relation with outcome in children. J Pak Med Assoc. Mar 2010;60(3):175-8. [Medline].
Goss JA, Shackleton CR, Maggard M, et al. Liver transplantation for fulminant hepatic failure in the pediatric patient. Arch Surg. Aug 1998;133(8):839-46. [Medline].
Baccarani U, Adani GL, Sainz M, et al. Human hepatocyte transplantation for acute liver failure: state of the art and analysis of cell sources. Transplant Proc. Jul-Aug 2005;37(6):2702-4. [Medline].
Faraj W, Dar F, Bartlett A, Melendez HV, Marangoni G, Mukherji D, et al. Auxiliary liver transplantation for acute liver failure in children. Ann Surg. Feb 2010;251(2):351-6. [Medline].
Hattori H, Higuchi Y, Tsuji M, et al. Living-related liver transplantation and neurological outcome in children with fulminant hepatic failure. Transplantation. Mar 15 1998;65(5):686-92. [Medline].

